| Document |
Document Title |
|
WO/2006/104530 |
Conjugates that are useful for delivering a therapeutic agent to kidney cells are described. The conjugates include saccharides that target the conjugates to kidney cells. The targeting portion of conjugate preferably employs the bi-ante...
|
|
WO/2006/100091 |
The invention relates to compounds of formula A-(B)x-C where A = a reducing di- or tri-saccharide, B = 2 - 4C polyvalent alcohol or the derivatives thereof, C = a branched or unbranched, saturated or unsaturated, fatty alcohol with 8 to ...
|
|
WO/2006/099245 |
Methods of treating sirtuin related disorders and compounds useful in treating sirtuin related disorders are described.
|
|
WO/2006/098699 |
Glycolipids of branched chain alkyl oligosaccharides according to this patent comprise of a primary alcohol branched in the 2-position and an oligosaccharide, covalently bond to the alcohol in either &agr - or β-linkage (shown in Formul...
|
|
WO/2006/096665 |
A method of synthesizing Rl, R2-substituted-4' (ax. or eq.)-OH anthracyclines and their corresponding salts of Formula (1) from daunorubicin or N-Trifluoroacetyl-4- Rl - derivatives of daunorubicin, wherein Rl is defined as H, OH, and 4'...
|
|
WO/2006/096606 |
Compounds for the inducing apoptosis in cancer cells are described. The described compounds induce the translocation of protein kinase C-&dgr to the mitochondria and the phosphorylation of mitochondrial phospholipid scramblase 3. The com...
|
|
WO/2006/093352 |
A compound represented by the general formula (1') or a salt thereof: (1') wherein R represents an aldopyranose residue, R2 represents a hydrocarbon group having 2 to 18 carbon atoms which may have a substituent; R3 represents an acyl gr...
|
|
WO/2006/093202 |
A phloroacyphenone glycoside represented by the general formula (1): wherein R1 represents an isopropyl, isobutyl or sec-butyl group.
|
|
WO/2006/091580 |
Fuels and fuel components comprising starch are provided, as well as methods for operating a combustor such as a boiler or an internal combustion engine by feeding a starch fuel to the combustor. The starch may be a common starch or a mo...
|
|
WO/2006/088017 |
An oligosaccharide having at an end thereof a 4-position halogenated galactose residue represented by the following formula (I); a transferase inhibitor containing the oligosaccharide; a method of inhibiting a sugar chain elongation reac...
|
|
WO/2006/088256 |
A process for producing a glycoside compound having a trans configuration selective for the 2-position hydroxy group from (a) a furanose compound or pyranose compound and (b) an alcohol compound, characterized in that use is made of a fu...
|
|
WO/2006/083019 |
Disclosed is an amyloid β protein aggregation inhibitor. The inhibitor comprises a compound represented by the chemical structure composed of a monosaccharide or a sugar chain having two or more monosaccharides, wherein a part or all of...
|
|
WO/2006/077851 |
Disclosed is a compound having an excellent platelet agglutination inhibitory effect. Specifically disclosed is a quinolone derivative characterized by having an amide group at the 3-position which is substituted with a substituent havin...
|
|
WO/2006/067883 |
A novel nonionic surfactant consisting of a cellooligosaccharide derivative wherein the position of introduction of hydrophobic groups is unevenly distributed along the main chain of cellulose; and a process for producing the same. There...
|
|
WO/2006/067173 |
The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being com...
|
|
WO/2006/067173 |
The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being com...
|
|
WO/2006/066060 |
A hydrophilically modified polyol compound comprising from 5 to 11 hydroxy moieties, wherein at least one hydroxy moiety further comprises one or more ethoxy moiety, further comprising an anionic capping unit, a cationic capping unit or ...
|
|
WO/2006/064914 |
This invention provides a novel compound having irreversible inhibitory activity against neuraminidase, and a therapeutic agent and a detecting agent for neuraminidase-related diseases. Specifically, there are provided a compound of form...
|
|
WO/2006/066059 |
Hydrophobically modified polyol compounds comprising from 5 to 11 hydroxy moieties, wherein at least one hydroxy moiety further comprises an alkoxy moiety, and one of the hydroxy or alkoxy moieties comprises an anionic capping unit; comp...
|
|
WO/2006/066020 |
Activated polymeric bicine derivatives such as, formula (A) as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.
|
|
WO/2006/058597 |
The invention relates to the novel compounds of formula (I) wherein T, E, R, R , R , R1, R2 and R2 are defined as in claim 1. The novel compounds are suitable as antidiabetics.
|
|
WO/2006/060728 |
The present invention concerns methods and compositions involving modified LcrV proteins from Yersinia bacteria. These methods and compositions can be employed to invoke an immune response in a subject against the bacteria, while not sup...
|
|
WO/2006/058669 |
The present invention relates to aminotetrahydropteridines and processes for the manufacture thereof. In particular, the present invention relates to a process for the manufacture of aminotetrahydrobiopterine. Said compound is an inhibit...
|
|
WO/2006/060728 |
The present invention concerns methods and compositions involving modified LcrV proteins from Yersinia bacteria. These methods and compositions can be employed to invoke an immune response in a subject against the bacteria, while not sup...
|
|
WO/2006/056604 |
Novel levodopa beta-glycosyl derivatives with improved bioavailability and stability, methods of their preparation and use for the treatment of pathological central and peripheral nervous system dysfunctions, neuromotor conditions and ca...
|
|
WO/2006/057406 |
A novel compound causing intraoral pungency, such as acridity, represented by the following structural formula (I).
|
|
WO/2006/053972 |
The invention relates to silanizing agents comprising a saccharide end group and to the use thereof for the functionalization of solid supports. The invention also relates to solid supports that have been functionalized by said silanizin...
|
|
WO/2006/055437 |
The present invention relates to synthetic methods for producing glycodendrimer reagents from disaccharides having a sulhydryl group
|
|
WO/2006/054304 |
This invention provides for the use of a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product ...
|
|
WO/2006/053972 |
The invention relates to silanizing agents comprising a saccharide end group and to the use thereof for the functionalization of solid supports. The invention also relates to solid supports that have been functionalized by said silanizin...
|
|
WO/2006/052930 |
The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2”-O-positions as well as their preparation and use as prophylactic or therapeutics against microbial infection.
|
|
WO/2006/052886 |
The invention relates to metabolites of certain [1,4]diazepino[6,7,1-i~]quinoline derivatives and methods of preparation and use thereof. Specifically, the invention relates to compounds of formula I wherein the various substituents are ...
|
|
WO/2006/048165 |
The invention relates to preparations containing (a) alkyl- and/or alkenyl oligoglycosides of formula (I), R1O-[G]p, in which R1 represents a linear or branched alkyl- and/or alkenyl group comprising between 4 and 22 carbon atoms, G repr...
|
|
WO/2006/046674 |
A medicinal composition for preventing or treating hepatitis C virus infection which contains an extract of a plant belonging to the genus Polygala as the active ingredient. It is preferable that this medicinal composition contains an ex...
|
|
WO/2006/043705 |
A cubic liquid crystal composition, characterized by containing at least one amphiphilic compound which is represented by the general formula (1) and has an IV/OV value of 0.65 to 0.95 and water or an aqueous solvent: (1) wherein R is a ...
|
|
WO/2006/041902 |
Compositions and methods for using nordihydroguaiaretic acid (NDGA) derivatives for preventing the expression of MDR-1 gene and the synthesis of PgP protein or reversing multiple drug resistance in cells, and for using NDGA derivatives i...
|
|
WO/2006/037159 |
A method of identifying biologically active compounds with defined selectivity profile comprises: (c) designing a library of compounds of formula (1) to scan molecular diversity; and (d) assaying the library of compounds in at least two ...
|
|
WO/2006/038440 |
A novel process for producing a phenylglycoside derivative which comprises using an unprotected sugar as a starting material and causing a compound having a phenolic hydroxy group to act on the sugar. The phenylglycoside derivative is at...
|
|
WO/2006/038221 |
A process for the production of steviosides from Stevia rebaudiana Bertoni includes extraction of comminuted plant material by directly injecting steam into the extractor followed by filtration to get aqueous extract and alkali treatment...
|
|
WO/2006/037185 |
A compound of the general formula (I): wherein R1, R2, X1, X1', X2, X2', X3, X3', X4, X4' and X5 define various substituents and p is 0, 1 or 2. The invention also relates to use of the compounds as anti-microbial agents.
|
|
WO/2006/034489 |
A compound of the formula (I) A method is also provided for treating diabetes and related diseases employing the above compound alone or in combination with another therapeutic agent.
|
|
WO/2006/029837 |
The invention relates to a method for directly reacting an amino alcohol, which has at least one hydroxyl function and at least one amino function, with an organic compound as a substrate, which comprises at least one acidic, functional ...
|
|
WO/2006/029221 |
Novel compounds such as compounds designated herein as Xanifolia-Y or -Y3, -Y1, -Y2, -Y8, -Y9 and -Y10 are disclosed. These compounds have anticancer activity. The compounds of the present invention are obtainable from plants in the sapi...
|
|
WO/2006/029065 |
Disclosed are prodrugs of inactivators of 06-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the (3-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrug...
|
|
WO/2006/029221 |
Novel compounds such as compounds designated herein as Xanifolia-Y or -Y3, -Y1, -Y2, -Y8, -Y9 and -Y10 are disclosed. These compounds have anticancer activity. The compounds of the present invention are obtainable from plants in the sapi...
|
|
WO/2006/027784 |
A novel group of aminoglycosides which share some structural features of currently available aminoglycosides, while also having significant structural differences, is disclosed. The similarity enables these aminoglycosides to be highly p...
|
|
WO/2006/028229 |
A dicarboxylic acid compound obtained by oxidative decomposition of the second sugar residue of the sugar chain of a pradimicin group antibiotic, namely, an antibiotic composed of a benzonaphthacenequinone skeleton, D-amino acid side cha...
|
|
WO/2006/027987 |
A compound usable as a preventive or therapeutic agent for urination disorders. It is a compound represented by the following general formula (1), a pharmacologically acceptable salt of the compound, or a hydrate or solvate of either. Al...
|
|
WO/2006/026639 |
A process for the preparation of an alkoxylated sucrose ester including the steps of: forming an initial reaction mixture of a sucrose ester and from about 0.01% to about 5% of a catalyst; and forming an initial reaction product by react...
|
|
WO/2006/026638 |
Purified alkoxylated sucrose esters of the formula (I): wherein R is independently selected from: COR'; (CH2CH2O)xH; and (CH2CH2O)x COR'; wherein R' is a fatty acid compound having from about 2 to about 28 carbon atoms; and wherein x is ...
|
